Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies

Mostofa, Agm; Hossain, Kamal; Basak, Debasish; Sayeed, Muhammad Shahdaat Bin

doi:10.3389/fphar.2017.00295

Cited by 86 publications

(73 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The downregulation of STAT3 activation was associated with a reduction in JAK2 and c-Src activity (Zhu et al, 2016). Recent preclinical studies suggested the potential of TQ in adjuvant therapy with other chemotherapeutic agents (reviewed in Mostofa et al, 2017). In another study in BALB/c mice transplanted with mouse epithelia breast cancer EMT6/P cell line, TQ in combination with melatonin significantly decreased the tumor size, induced tumor cell death, decreased VEGF expression, and activated anticancer immune response by increasing serum interferon (INF)-g level (Odeh et al, 2018).…”

Section: Phytochemicals In Pre-clinical Trialsmentioning

confidence: 99%

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

et al. 2020

View full text Add to dashboard Cite

Cancer is a severe health problem that continues to be a leading cause of death worldwide. Increasing knowledge of the molecular mechanisms underlying cancer progression has led to the development of a vast number of anticancer drugs. However, the use of chemically synthesized drugs has not significantly improved the overall survival rate over the past few decades. As a result, new strategies and novel chemoprevention agents are needed to complement current cancer therapies to improve efficiency. Naturally occurring compounds from plants known as phytochemicals, serve as vital resources for novel drugs and are also sources for cancer therapy. Some typical examples include taxol analogs, vinca alkaloids such as vincristine, vinblastine, and podophyllotoxin analogs. These phytochemicals often act via regulating molecular pathways which are implicated in growth and progression of cancer. The specific mechanisms include increasing antioxidant status, carcinogen inactivation, inhibiting proliferation, induction of cell cycle arrest and apoptosis; and regulation of the immune system. The primary objective of this review is to describe what we know to date of the active compounds in the natural products, along with their pharmacologic action and molecular or specific targets. Recent trends and gaps in phytochemical based anticancer drug discovery are also explored. The authors wish to expand the phytochemical research area not only for their scientific soundness but also for their potential druggability. Hence, the emphasis is given to information about anticancer phytochemicals which are evaluated at preclinical and clinical level.

show abstract

Section: Phytochemicals In Pre-clinical Trialsmentioning

confidence: 99%

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…There are some reported studies on the anticancer efficacy of Tq. Recent reports suggest Tq to be effective in adjuvant cancer therapies (Mostofa, Hossain, Basak, & Sayeed, 2017). The effect of Tq has been proven against a variety of cancer types which include the cancer of bladder (Iskender, Izgi, & Canatan, 2016), breast (Dastjerdi, Mehdiabady, Iranpour, & Bahramian, 2016), colon (Chen et al, 2015) lung (Yang, Kuang, Lv, & Yan, 2015), and prostate (Richards, Jones, Hughes, Benghuzzi, & Tucci, 2006).…”

Section: Introductionmentioning

confidence: 99%

Thymoquinone attenuates phosphorylation of AKT to inhibit kidney cancer cell proliferation

Dera

Rajagopalan

2019

J Food Biochem

View full text Add to dashboard Cite

Thymoquinone (Tq) is an active compound from Nigella sativa which is used in traditional medicine. The effect of Tq on kidney cancer and the pathway of action remain unproven. Herein, we report the anticancer properties of Tq on kidney cancer cells. Tq demonstrated anti‐proliferative effects in A498 cells with a GI50 value of 40.07 µM and Caki‐1 cells with a GI50 of 51.04 µM by the MTT assay. Tq exhibited nuclear fragmentation and inhibited trans‐endothelial migration of A498 and Caki‐1 cells in a dose‐responsive manner. Time‐dependent increase in Annexin V‐positive cells and sub‐G0/G1 cell population was observed post‐Tq treatment. The compound increased Bax protein levels and reduced Bcl‐2 protein levels dose dependently in cells, thereby favoring apoptosis. Tq decreased the phosphorylation of Akt in both kidney cell types. The results suggest effective anticancer activity of Tq on kidney cancer cells which may be mediated by the Akt pathway. Practical applications Results from the current investigation will through more light on the mechanistic pathway of Tq activity on the inhibition of kidney cancer cell proliferation. The output of this preclinical in vitro study may be translated into better chemotherapeutics of Tq and its analogs to treat kidney cancer. However, a detailed investigation on in vivo models is recommended.

show abstract

“…Among its pharmacological properties, TQ displays antioxidant, antihistamine, immunomodulatory, anti-inflammatory, anti-microbial, and neuroprotective activities [2,[5][6][7]10,11]. It was also reported that TQ is a potent anticancer agent and has potential in the prevention and treatment of breast, colon, and ovarian cancers [4,9,10,[12][13][14].…”

mentioning

confidence: 99%

Non-Lamellar Liquid Crystalline Nanocarriers for Thymoquinone Encapsulation

2019

View full text Add to dashboard Cite

Owing to their unique structural features, non-lamellar liquid crystalline nanoparticles comprising cubosomes and hexosomes are attracting increasing attention as versatile investigative drug carriers. Background: Depending on their physiochemical characteristics, drug molecules on entrapment can modulate and reorganize structural features of cubosomes and hexosomes. Therefore, it is important to assess the effect of guest molecules on broader biophysical characteristics of non-lamellar liquid crystalline nanoparticles, since drug-induced architectural, morphological, and size modifications can affect the biological performance of cubosomes and hexosomes. Methods: We report on alterations in morphological, structural, and size characteristics of nanodispersions composed from binary mixtures of glycerol monooleate and vitamin E on thymoquinone (a molecule with wide therapeutic potentials) loading. Results: Thymoquinone loading was associated with a slight increase in the mean hydrodynamic nanoparticle size and led to structural transitions from an internal biphasic feature of coexisting inverse cubic Fd3m and hexagonal (H2) phases to an internal inverse cubic Fd3m phase (micellar cubosomes) or an internal inverse micellar (L2) phase (emulsified microemulsions, EMEs). We further report on the presence of “flower-like” vesicular populations in both native and drug-loaded nanodispersions. Conclusions: These nanodispersions have the potential to accommodate thymoquinone and may be considered as promising platforms for the development of thymoquinone nanomedicines.

show abstract

Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies

Cited by 86 publications

References 97 publications

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

Thymoquinone attenuates phosphorylation of AKT to inhibit kidney cancer cell proliferation

Non-Lamellar Liquid Crystalline Nanocarriers for Thymoquinone Encapsulation

Contact Info

Product

Resources

About